Company Description
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was...
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
Valuation
Price to Sales Ratio
909.01
Price to Book Ratio
2.27
Enterprise Value to EBITDA
-1.85
Enterprise Value to Sales
158.89
Efficiency
Total Asset Turnover
0.00
Liquidity
Current Ratio
18.95
Quick Ratio
18.95
Cash Ratio
17.16
Profitability
Operating Margin
-16,106.63
Pretax Margin
-16,762.43
Net Margin
-16,762.43
Return on Assets
-43.16
Return on Equity
-51.00
Return on Total Capital
-43.39
Capital Structure
Total Debt to Total Assets
15.24
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. Raymond J. Tesi | 64 | 2015 | Chairman, President, Chief Executive Officer & CMO |
Mr. David J. Moss | 49 | 2015 | Chief Financial Officer, Secretary & Treasurer |
Dr. Mark Lowdell | 57 | 2015 | Chief Scientific & Manufacturing Officer |
Mr. Joshua S. Schoonover | - | - | Associate General Counsel |
Dr. Edgardo Baracchini | 60 | 2019 | Director |
Insider Actions
03/22/2022 |
Raymond J. Tesi President and CEO; Director |
23,724 | Award at $8.43 per share. | 199,993 |
03/22/2022 |
Mark Lowdell Chief Scientific Officer |
23,590 | Award at $8.43 per share. | 198,863 |
03/22/2022 |
David J. Moss CFO, Treasurer & Secretary |
17,793 | Award at $8.43 per share. | 149,994 |
03/22/2022 |
J. Kelly Ganjei Director |
17,793 | Award at $8.43 per share. | 149,994 |
11/17/2021 |
Scott Juda Director |
2,500 | Acquisition at $13.55 per share. | 33,875 |
11/03/2021 |
Raymond J. Tesi President and CEO; Director |
3,626 | Disposition at $20 per share. | 72,520 |
11/03/2021 |
Mark Lowdell Chief Scientific Officer |
701 | Disposition at $20 per share. | 14,020 |
11/03/2021 |
David J. Moss CFO, Treasurer & Secretary |
1,025 | Disposition at $20 per share. | 20,500 |
10/27/2021 |
Raymond J. Tesi President and CEO; Director |
6,517 | Disposition at $20 per share. | 130,340 |
10/27/2021 |
Mark Lowdell Chief Scientific Officer |
2,357 | Disposition at $20 per share. | 47,140 |
10/27/2021 |
David J. Moss CFO, Treasurer & Secretary |
2,079 | Disposition at $20 per share. | 41,580 |
10/25/2021 |
David J. Moss CFO, Treasurer & Secretary |
13 | Disposition at $20 per share. | 260 |
10/22/2021 |
Raymond J. Tesi President and CEO; Director |
23,616 | Disposition at $20 per share. | 472,320 |
10/22/2021 |
Mark Lowdell Chief Scientific Officer |
400 | Disposition at $20 per share. | 8,000 |
10/22/2021 |
David J. Moss CFO, Treasurer & Secretary |
1,142 | Disposition at $20 per share. | 22,840 |
09/03/2021 |
Xencor, Inc. |
108,000 | Derivative/Non-derivative trans. at $7.8 per share. | 842,400 |
08/25/2021 |
Raymond J. Tesi President and CEO; Director |
30,000 | Derivative/Non-derivative trans. at $3.91 per share. | 117,300 |
07/16/2021 |
David J. Moss CFO, Treasurer & Secretary |
25,000 | Derivative/Non-derivative trans. at $3.91 per share. | 97,750 |
07/13/2021 |
Timothy J. Schroeder Director |
14,480 | Disposition at $27.63 per share. | 400,082 |
MarketWatch News on INMB
-
INmune Bio downgraded to neutral from buy at B. Riley
- Tomi Kilgore
-
INmune Bio stock price target cut to $7 from $14 at B. Riley
- Tomi Kilgore
-
Robinhood investors are propping up this stock market, says JPMorgan
- Barbara Kollmeyer
-
Analyst Raises Price Targets on 3 Smaller Alzheimer's Stocks
- Barron's Online
-
INmune Bio stock price target raised to $42 from $32 at Maxim Group
- Tomi Kilgore
-
INmune Bio started at buy with $29 stock price target at B. Riley
- Tomi Kilgore
-
INmune Bio stock price target raised to $32 from $16 at Maxim Group
- Tomi Kilgore
-
INmune Bios started at buy with $13 stock price target at Maxim Group
- Tomi Kilgore
Other News on INMB
-
INmune Bio: Possibly The Once In A Lifetime Dip
- Seeking Alpha
-
PLG, ZTEK and BBAI among mid-day movers
- Seeking Alpha
-
INmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript
- Motley Fool
-
Notable earnings after Thursday's close
- Seeking Alpha
-
Hypotheses Underlying Alzheimer's Drug Development
- Seeking Alpha
-
KNDI, LILM and ADN among mid- day movers
- Seeking Alpha
-
INmune Bio, Inc. (INMB) Q4 2021 Earnings Call Transcript
- Motley Fool
-
- Edgar Online - (EDG = 10Q, 10K)
-
Anavex Life Sciences: My Thoughts On Their AD Therapy
- Seeking Alpha
- Loading more headlines...